Aptus Pharma Limited submitted its investor presentation for the financial year ended 31st March 2026 to BSE Limited under SEBI Listing Regulations (Regulation 30). The presentation was also uploaded to the company's website, www.aptus-pharma.com.

Company Overview & Business Model

Aptus Pharma Ltd. is a fast-growing pharmaceutical company established in 2010. It operates on an asset-light, marketing- and distribution-focused business model, outsourcing manufacturing to WHO-GMP-certified contract manufacturers through loan licensing and purchase order arrangements. This model is designed to conserve capital and redirect resources toward sales growth and brand building. The company has a diversified portfolio of 250+ formulations across three key verticals: Pharma Formulation (prescription-based branded generics), Consumer Products (OTC, wellness, personal care), and International Market & Export Services.

The company reports having relationships with over 25,000 doctors, a field force of 150+ professionals, and generates 50,000+ prescriptions per day. It has formal loan licence agreements with two manufacturing facilities in Gujarat and contracts with 10+ other WHO-GMP-compliant manufacturing partners.

Leadership & Management

The management team is led by Managing Director and Promoter Tejash M. Hathi. Other key personnel include CEO and Promoter Ghanshyam V. Pansuriya, CFO Kapil H. Chandarana, and Vice President-Pan-India Operations Nirav J. Pandya. The board includes Non-Executive Directors Riddhish N. Tanna and Chetan S. Lalseta, Director Jyotiben H. Chandarana, and Independent Directors Vikas R. Jobanputra and Sejal Harit Palan. Company Secretary & Compliance Officer (KMP) is CS Mohini H. Gandhi.

Financial Performance for FY26

Profit & Loss Statement (₹ in Crore):

  • Revenue from Operations: ₹46.57 (FY25: ₹24.56), up 89.7% Year-on-Year (YoY).
  • Gross Profit: ₹25.20 (FY25: ₹15.52), up 62.4% YoY. Gross Profit Margin: 54.1% (FY25: 63.2%).
  • EBITDA: ₹7.45 (FY25: ₹4.85), up 53.6% YoY. EBITDA Margin: 16.0% (FY25: 19.7%).
  • Profit Before Tax (PBT): ₹6.37 (FY25: ₹4.20), up 52.0% YoY.
  • Profit After Tax (PAT): ₹4.62 (FY25: ₹3.10), up 49.0% YoY. PAT Margin: 9.9% (FY25: 12.6%).
  • Basic EPS: ₹7.78 (FY25: ₹6.37).

H2 FY26 Profit & Loss Highlights (₹ in Crore):

  • Revenue from Operations: ₹32.18 (H2 FY25: ₹14.80).
  • Gross Profit: ₹16.65 (H2 FY25: ₹9.46). Gross Profit Margin: 51.7% (H2 FY25: 63.9%).
  • EBITDA: ₹4.49 (H2 FY25: ₹2.88). EBITDA Margin: 14.0% (H2 FY25: 19.4%).
  • PAT: ₹2.87 (H2 FY25: ₹1.79). PAT Margin: 8.9% (H2 FY25: 12.1%).
  • Basic EPS: ₹4.19 (H2 FY25: ₹9.39).

Balance Sheet as of 31st March 2026 (₹ in Crore):

  • Total Equity and Liabilities: ₹43.53 (Mar'25: ₹21.92).
  • Shareholders' Funds: ₹23.35 (Mar'25: ₹6.97), comprising Share Capital of ₹6.86 (Mar'25: ₹5.00) and Reserves and Surplus of ₹16.49 (Mar'25: ₹1.97).
  • Total Assets: ₹43.53 (Mar'25: ₹21.92).
  • Current Assets: ₹35.24 (Mar'25: ₹19.74), including Inventories of ₹13.57 (Mar'25: ₹7.06) and Trade Receivables of ₹18.76 (Mar'25: ₹5.64).
  • Cash & Bank Balance: ₹1.03 (Mar'25: ₹5.21).

Strategic Roadmap & Outlook

The company outlined a strategic growth roadmap targeting 2028-2029. Key objectives include:

  • Global Expansion by March 2028: Targeting entry into markets across Asia (e.g., UAE, Malaysia), Africa (e.g., Kenya, Uganda), and Latin America (e.g., Brazil, Argentina).
  • Manufacturing Expansion by March 2028: Aims to evolve into an integrated manufacturer, targeting 20% of production from own manufacturing facilities to strengthen quality control and supply-chain efficiency.
  • Pan-India Footprint by 2029: The goal is to build a diversified multi-vertical pharmaceutical platform with a strong domestic footprint and a global presence.

The Managing Director's statement emphasized a focus on profitable growth, disciplined capital allocation, and creating sustainable long-term value for shareholders.